

Publications of the Week

Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab in Patients With Treatment-Naïve or Relapsed/Refractory Mantle Cell Lymphoma: Phase Ib Trial

First Author: Tycel Phillips | Senior Author: Stephen Smith *(pictured)*
Haematologica | Fred Hutch and UW



This multicenter, open-label, phase Ib study assessed the safety and efficacy of acalabrutinib, bendamustine, and rituximab (ABR) in treatment-naïve (TN) and relapsed or refractory mantle cell lymphoma (MCL). The authors provide evidence that ABR was safe and efficacious, supporting further study in patients with TN MCL. [Abstract](#)

[View All Publications](#)

Awards

Steven Kahn Receives Banting Medal for Scientific Achievement

UW Medicine



Dr. Steven Kahn *(pictured)* is the 2025 recipient of the American Diabetes Association Banting Medal for Scientific Achievement . This is the highest scientific award from the American Diabetes Association. Given in memory of Sir Frederick Banting, the Banting Medal is awarded annually to honor a highly meritorious career achievement in the field of diabetes research. [Read More](#)

Newborn Jaundice Detection Tool Wins Grand Prize at UW Health Innovation Challenge

GeekWire



A trio of students from UW won the grand prize at the UW's Hollomon Health Innovation Challenge for their non-invasive jaundice-detecting technology. The challenge, according to winners Lillian Tran *(picture, left)*, Tejoram Vivekanandan *(middle)* and Nana Wang *(right)*, is that much of the current technology for identifying jaundice doesn't do a good job recognizing the condition in babies with more melanin in their skin. [Read More](#)

[View All Awards](#)

Local News

Looking Back on UW Innovations After Five Years of COVID-19

UW Magazine



Five years ago this winter, the University of Washington became a leader in the local and global response to COVID-19. That infectious disease—which had its first confirmed American case in Washington state—created a worldwide pandemic and altered life for all of us. Thankfully, COVID-19 no longer dominates our daily conversation the way it used to. [Read More](#)

Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma

Adaptive Biotechnologies



Adaptive Biotechnologies, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, has announced that it has launched an upgraded version of its clonoSEQ assay for measurable residual disease detection in diffuse large B-cell lymphoma using circulating tumor DNA. [Read More](#)

Prostate Cancer Is Not a Death Knell, Study Shows


UW Medicine



Prostate cancer statistics can look scary: 34,250 U.S. deaths in 2024. 1.4 million new cases worldwide in 2022. Dr. Bruce Montgomery *(pictured)*, a UW Medicine oncologist, hopes that patients won't see these numbers and just throw up their hands in fear or resignation. For more advanced prostate cancer, the number of effective treatments developed has markedly increased. [Read More](#)

Scientists Create Method for Designing Proteins That Can Bind and Sense a Range of Small Molecules

Phys Org



Using artificial intelligence, a team of scientists led by Nobel Prize winner Dr. David Baker *(pictured)* at the University of Washington has created a computational method for generating proteins that bind and signal a wide range of small molecules with great effectiveness. Dr. Baker won the 2024 Nobel Prize in Chemistry for computational protein design. [Read More](#)

World's First Crowd-Sourced Neuroscience Study Aims to Understand How Our Brains Predict the Future


Allen Institute



An international collaboration of over 50 neuroscientists and researchers is pioneering a new approach to understanding the brain: the world's first crowd-sourced and designed neuroscience study. The goal is to shed light on predictive processing, the brain's ability to anticipate future events based on past experiences. The experiments began this month at the Allen Institute. [Read More](#)

New Seattle Lab Building Sees Early Success Drawing Tenants with Incubator Program

Puget Sound Business Journal



It's been less than half a year since 222 Fifth opened, but the ten-story life science property has already attracted six startup tenants. And the owners are betting an on-site incubator program will help draw even more tenants to the property. The opening of the nearly 200,000-square-foot speculative project came amid an improving environment for the life science sector. [Read More](#)



Upcoming Events in Seattle

March 25
4:30 PM

BRI's Open House
Benaroya Research Institute

March 26
9:30 AM

Cell Type Taxonomies A-Z Webinar Series: Programmatic Access to ABC Atlas Data
Online

April 23
11:00 AM

Life Science Innovation Northwest 2025
Seattle Convention Center

April 28
8:30 AM

BRI Immunology Symposium: New Horizons in Immunity and Disease
Town Hall Seattle

May 1
8:00 AM

Engineering Biology Research Consortium 2025 Annual Meeting
University of Washington

[View All Events](#) | [Submit an Event](#)



Science Jobs in Seattle

Executive Director, SeaBridge
Allen Institute

Clinical Assistant or Associate Professor, Pulmonology
Fred Hutch

Research Technician II, Joag Lab
Seattle Children's

Research Scientist/Engineer 5
UW

Medical Science Liaison, Neurology
TSP

[View 75 Other Science Jobs](#) | [Submit a Job](#)

Article: To Postdoc or Not to Postdoc?
Decision-Making Tips



STEMCELL™
TECHNOLOGIES
[LEARN MORE](#)

Submit your articles and events by reaching out to us at info@scienceinseattle.com.

BROUGHT TO YOU BY



STEMCELL Technologies
Products | Services

STEMCELL Science News
Free Weekly Updates on Your Field

The Stem Cell Podcast
Interviews and Updates
on Stem Cell Science